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Background: Preoperative screening for thrombophilias in free ﬂap candidates may be
cost-effective. Methods: We developed a model for thrombogenic ﬂap complications
using reported thrombophilia prevalences and thromboembolic risk ratios, as well as
free ﬂap complication rates from our institution. We performed a break-even and in-
cremental cost-effective ratio analysis for several screening and intervention scenarios.
Results:Ourthromboticfreeﬂapcomplicationrateis4.9%.Afullthrombophiliascreen
breaks even when the cost of complication exceeds $57000 per patient; a limited screen
breaks even at $39000, and a scenario in which all patients undergo chemoprophylaxis
breaks even at $49000. Incremental cost-effective ratio analyses estimate a cost per
avoided ﬂap complication of $33638 for a full panel scenario, $15617 for a limited
panel scenario and $25455 for an all therapy scenario. Conclusions: Our analyses
show that preoperative thrombophilia screening may be a cost-effective measure for the
prevention of free ﬂap thrombotic complications.
Free tissue transfer is a commonly performed reconstructive surgical procedure. An
estimated 19000 microsurgical free tissue transfers were performed during 2008 in the
United States for a broad range of reconstructive indications.1 Free ﬂap complications are
expensive, morbid, and psychologically stressful for the patient and equally disconcerting
for the surgeon. Identiﬁcation of preoperative patient risk factors may facilitate prevention
of intraoperative and postoperative adverse events.
Thrombosis represents a signiﬁcant source of ﬂap complications and may lead to
reoperation, extended hospital stays, ﬂap necrosis, and loss. For all types of free ﬂaps,
reported thrombotic ﬂap complication rates requiring reoperation range between 3% and
∗Presented at the 89th Annual Meeting of the Association of Academic Plastic Surgeons in San Antonio, Texas,
March 20 through March 23, 2010.
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12%.2-9 Thrombotic events are typically attributed to mechanical factors; however, several
case reports of thrombophilia associated with ﬂap failure have been reported,10-14 and
thrombophilias in free ﬂap patients have received recent attention in the literature.12,15
The association between thrombotic ﬂap complications and thrombophilias has not been
rigorously studied. A few small investigations reported conﬂicting ﬁndings, but none have
been adequately powered to establish causal effect.16,17 However, acquired and genetic
thrombophilias affect approximately 25% of the population18 and are known to contribute
tothrombosisinavarietyofsettings.Takentogether,theseobservationspointtoapotentially
signiﬁcant relationship between thrombophilias and thrombotic ﬂap complications.
Current knowledge of the relative risks for thrombosis imposed by thrombogenic con-
ditions comes from studies on venous thromboembolism (VTE) and arterial thrombosis in
normal and thrombophiliac cohorts. In patients with known thrombophilia, a 1.7- to 11-
fold annual relative risk of initial VTE is observed compared to normal counterparts.18−21
This corresponds to an annual incidence of initial VTE of 0.25% to 1.9% for patients with
thrombophilia compared with 0.05% annual incidence for normal populations. The role
of thrombophilias in arterial thromboembolic events is less well established but is associ-
ated with antiphospholipid syndrome14,22 and hyperhomocysteinemia,23 but not consis-
tently with other thrombophilias.
Venous thromboembolism incidence is increased in patients with malignancy,24 and
in trauma patients,25 conditions often found in free tissue transfer candidates. In addition,
prospective studies of VTE in asymptomatic thrombophiliacs evidence that more than
half of ﬁrst VTE events occur in association with trauma, surgery, or puerperium.20,26
Taken together, it is plausible that thrombophilias contribute to thrombotic complications
inmicrovascularsurgery,andthatundiagnosedthrombophiliasunderlieagreaterproportion
of ﬂap complications than is currently recognized.
Wesoughttodevelopamodeltoestimatethecost-effectivenessofpreoperativethrom-
bophilia screening for patients undergoing free tissue transfer. The risk of thrombosis at-
tributable to a thrombophilia during free ﬂap surgery is not known, and the relative risk
ratios for thrombophiliacs versus normal cohorts have not been reported. We posit that ra-
tional proxies for the relative risks posed by thrombophilias in the setting of microvascular
surgery are those known for initial VTE events. This model assumes that the risk of throm-
bosis posed by microsurgery for both normal and thrombophiliac cohorts is comparable to
the annual risk of a ﬁrst VTE. Accordingly, for each of the inherited thrombophilias, we
identiﬁedthereportedriskratioforaninitialVTEforpreviouslyundiagnosedsubjects.18,21
In conjunction with the known prevalences of each thrombophilia, the proxy relative risks
allow estimation of the number of thrombotic ﬂap complications that are attributable to
thrombophilia that would, in turn, be potentially amenable to prophylactic interventions.
This rational and evidence-based approach allows exploration of the conditions under
which preoperative thrombophilia screening may be cost-effective. With the incorporation
of ﬁnancial data, this model enables assessment of the costs of screening and prophy-
lactically treating free tissue transfer patients relative to the costs of current baseline
practice. For cost-effectiveness analyses, we used a break-even analysis and incremental
cost-effectiveness ratio (ICER). The break-even point is deﬁned as the point at which a
variable, such as complication cost, renders the cost of an intervention scenario equal to
the cost of the baseline scenario. We applied the break-even analysis to determine the ﬂap
complication cost at which an intervention scenario and the baseline scenario break even
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in cost. The ICER is the ratio of the difference in costs between therapeutic interventions
to the difference in effects between interventions. An ICER is expressed in dollars per unit
of health gained, and ICER analysis is used in health care economics to determine the
additional cost per unit of health beneﬁt gained when comparing one medical intervention
with another. Each metric offers distinctive and informative insights on cost-effectiveness,
thus we incorporated both in the evaluation of various scenarios in our analysis.
Table 1. Institutional Free Flap Analysis∗
Thrombotic % Thrombotic
Flap Type Total Flaps (A) % Complications (B) % Complications (A/B)
ALT 28 10.6 1 7.7 3.6
DIEP 121 45.8 1 7.7 0.8
Face 1 0.4 0.0 0.0
Fibula 7 2.7 1 7.7 14.3
Gracilis 10 3.8 0.0 0.0
Latissimus dorsi 4 1.5 1 7.7 25.0
VRAM 18 6.8 1 7.7 25.0
RFF 52 19.7 2 15.4 3.8
Scapula 4 1.5 2 15.4 50.0
SGAP 5 1.9 2 15.4 40.0
SIEA 7 2.7 2 15.4 28.6
TRAM 6 2.3 0.0 0.0
Vastus lateralis 1 0.4 0.0 0.0
Total 264 100.0 13 100.0 4.9
∗ ALT indicates anterolateral thigh ﬂap; DIEP, deep inferior epigastric perforator ﬂap; RFF, radial forearm ﬂap;
SGAP, superior gluteal artery perforator ﬂap; SIEA, superﬁcial inferior epigastric artery perforator ﬂap; TRAM,
transverse rectus abdominis myocutaneous ﬂap; VRAM, vertical rectus abdominis ﬂap.
PATIENTS AND METHODS
We retrospectively reviewed all free tissue transfers performed by faculty within the Divi-
sion of Plastic Surgery at Brigham and Women’s Hospital over the period October 2004 to
October 2009. We identiﬁed cases in which reoperation was performed for vascular com-
promiseoftheﬂap.Athromboticcomplicationwasdeﬁnedasintraoperativedocumentation
of idiopathic thrombosis; speciﬁcally, we excluded cases in which a mechanical cause of
thrombosis was evident. From these data, we calculated a thrombotic complication rate for
ourfreeﬂapseries(Table1).Wereviewedpatientbillingrecordsforthecasesofthrombotic
complications and matched a control group of uncomplicated free ﬂaps by indication, year,
and ﬂap type. To establish the average cost of thrombotic ﬂap complications, the direct
costs for each operative admission period were compared between the 2 groups (Table 2).
We reviewed the literature on thrombophilia and identiﬁed those conditions that are
mostcommonlyimplicatedinclinicaldisease.Asaproxyfortherelativeriskofthrombosis
imposed by a thrombophilia in the perioperative period, we turned to the known risk ratios
for initial venous thromboembolism for each of the thrombophilias. In each case, we
chose the most conservative established risk ratio. Using values from our institution’s
laboratories, we then calculated the cost of screening for these conditions and ascertained
the sensitivities and speciﬁcities of each test (Table 3). We determined the cost of in- and
outpatient enoxaparin therapy for 1 month at our institution.
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Using these data, we developed a mathematic model to estimate the number and
cost of anticipated thrombotic complications for 4 scenarios, each with a cohort of 10000
patients. The Baseline Scenario included the total number and cost of ﬂap complications
with no preoperative screening. The Full Panel Scenario examined the total number and
cost of ﬂap complications, in addition to the cost of preoperative screening for every
patient for all thrombophilias and intervention for test-positive patients with 1 month of
prophylactic enoxaparin. We assumed 88% effectiveness of thrombosis prophylaxis based
upon reported ﬁgures from a meta-analysis.28 As a conservative measure, we limited the
model’s calculation of risk of thrombosis to 50% for each thrombophilia. The Limited
Panel Scenario described a lower-cost screen for a subset of thrombophilias that the model
predicted would capture 87% of the disease-positive patients. Assays were included on the
basisofthenumberoftest-positivepatientspredictedbythemodel,whichwasafunctionof
eachcondition’sprevalence,relativerisk,andtestsensitivity.Ouranalysiswasstructuredto
account for thrombotic events expected in patients suffering from thrombophilias excluded
from the limited panel (Table 3). Finally, the All Therapy Scenario assessed a circumstance
in which no preoperative screen was performed but all patients underwent prophylactic
enoxaparin therapy. We then compared the total cost and the absolute difference in ﬂap
failures of each intervention scenarios relative to the baseline and calculated a break-
even point and ICER for each comparison. The parameters used in the predictive model,
break-even, and ICER analyses are shown in Table 4.
Table 4. Model Assumptions
Model Variable Assumed Value
Patient population 10000
Flap cancellation rate 0%
Cost of screening panel∗ $ 1206
Cost of anticoagulation therapy per patient $ 2100
Efﬁcacy of anticoagulation therapy 88%
Cost of thrombotic complication per patient∗ $ 23246
Thrombotic complication rate 4.9%
∗Variable adjusted in cost-efﬁciency break-even analysis
RESULTS
We reviewed 264 free ﬂaps at our institution performed over a 5-year period. Thrombosis-
related complications occurred in 13 (4.9%) of ﬂaps (Table 1), leading to 5 ﬂap failures
(1.9%). Billing records showed an average cost of ﬂap complication over a case-controlled
uncomplicated ﬂap of $23246 (Table 2).
Through review of the literature, we identiﬁed the 9 most common thrombophilias as
factor VIII excess, activated protein C resistance, hyperhomocysteinemia, anticardiolipin
antibody, lupus anticoagulant, prothrombin G20210A mutation, protein S deﬁciency, an-
tithrombin deﬁciency, and protein C deﬁciency. We applied the known relative risks for
initial VTE (range, 2.5–11) for these conditions as proxy relative risks for thrombotic
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microsurgical complications (Table 3). Our institutional laboratory cost for a complete
thrombophilia screening panel was $1206 per patient, while a limited panel of the 5 throm-
bophilias predicted to cause 87% of complications was $572 per patient. The limited panel
includes activated protein C resistance, lupus anticoagulant, hyperhomocysteinemia, pro-
teinSdeﬁciency,andfactorVIIIexcess.Usingreportedthrombophiliaprevalencesandrisk
ratios and our complication rate of 4.9%, our model estimated that 73% of ﬂap thromboses
are attributable to thrombophilia, or an absolute rate of 3.6% of cases.
Assuming a theoretical cohort of 10000 free ﬂap candidates and applying known
prevalence and screening test sensitivity statistics for each of the included thrombophilias,
our model predicted a total of 2889 patients who would test positive for hypercoagulable
conditions in a preoperative screening panel. We assumed that no operative intervention
would be cancelled because of a positive screening test and that thrombosis prophylaxis
would consist of a thirty-day course of enoxaparin costing $2100 per patient. The efﬁcacy
of prophylactic therapy in such cases was assumed to be 88%, pursuant to prior validated
studies.
Break-even analyses demonstrated that a complete preoperative thrombophilia screen
(Full Panel Scenario) breaks even when the cost of thrombotic ﬂap complication exceeds
$57000 per patient. A limited thrombophilia screen that captures 87% of anticipated
thrombotic complications at a substantially reduced panel cost (Limited Panel Scenario)
breaks even when the cost of thrombotic ﬂap complication exceeds $39000 per patient.
Finally, prophylactic treatment of all patients with 1 month of enoxaparin therapy in the
absence of any preoperative screening (All Therapy Scenario) breaks even when the cost
of thrombotic ﬂap complication exceeds $49000 per patient (Table 5, Fig 1).
Table 5. Summary Results of Scenario Analyses∗
Cost per Thrombotic Break-Even
Scenario Patient Complications Point ICER
Baseline $ 1067 490 N/A N/A
Full panel $ 2186 171 $ 57000 $ 33638
Limited panel $ 1542 212 $ 39000 $ 15617
All therapy $ 2228 59 $ 49000 $ 25455
∗ICER indicates incremental cost-effectiveness ratio. Intervention scenario results are relative to baseline
scenario.
ICER analyses performed for each of the intervention scenarios compared to the
baseline scenario. For the Full Panel Scenario, the cost per avoided ﬂap complication was
$33638. For the Limited Panel Scenario, the cost was $15617 per avoided thrombotic ﬂap
complication,andintheAllTherapyScenario,thecostwas$25455peravoidedthrombotic
ﬂap complication (Table 5).
DISCUSSION
Anastomotic thrombosis is a principal concern in free ﬂap reconstructive surgery, and
efforts to limit this complication justify many of the care measures routinely employed
in the care of patients undergoing these procedures. Although thrombosis is sometimes
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secondarytomechanicalfactorsincludingexcessivevesselstretchorkinking,arterialand/or
venous thrombotic occlusion often occurs in the absence of any apparent technical con-
cerns.Increasingrecognitionofthispointhasrecentlyledtoheightenedinvestigationofthe
potential role of thrombophilias in free ﬂap surgery. The prevalence of thrombophilias in
the general population is approximately 15%, and thrombophilias have a well-established
causal relationship to venous thromboembolic events. While the contribution of throm-
bophilia conditions to thrombosis is unknown, it is likely that thrombophilias play a signif-
icant role in free ﬂap thrombotic complications that is under recognized.
$0
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000
 
$
-
 
 
 
$
5
,
0
0
0
$
1
0
,
0
0
0
$
1
5
,
0
0
0
$
2
0
,
0
0
0
$
2
5
,
0
0
0
$
3
0
,
0
0
0
$
3
5
,
0
0
0
$
4
0
,
0
0
0
$
4
5
,
0
0
0
$
5
0
,
0
0
0
$
5
5
,
0
0
0
$
6
0
,
0
0
0
$
6
5
,
0
0
0
$
7
0
,
0
0
0
$
7
5
,
0
0
0
$
8
0
,
0
0
0
$
8
5
,
0
0
0
$
9
0
,
0
0
0
$
9
5
,
0
0
0
$
1
0
0
,
0
0
0
Baseline Scenario
Full Panel Scenario
Limited Panel Scenario
All Therapy Scenario
Incremental Cost of Thrombotic Complication per Patient
S
c
e
n
a
r
i
o
 
C
o
s
t
 
p
e
r
 
P
a
t
i
e
n
t
Limited Panel Breakeven
$39,000
All Therapy Breakeven
$49,000
Full Panel Breakeven
$57,000
Figure 1. Break-even analysis demonstrates the break-even points for the 3 intervention scenarios
compared to baseline.
Our study represents the ﬁrst attempt to ascertain whether preoperative screening and
perioperative treatment for previously undiagnosed thrombophiliacs undergoing free ﬂap
procedures may be a cost-effective measure. Our theoretical model estimates that throm-
bophilias may account for up to 73% of nonmechanical thrombotic free ﬂap complications,
based on an overall institutional nonmechanical thrombotic free ﬂap complication rate
of 4.9%. It furthermore suggests that the cost of preoperatively screening all free ﬂap
candidates and prophylactically anticoagulating those who demonstrate tests positive for
thrombophilia conditions breaks even with status quo practice when the incremental cost
of thrombotic ﬂap complication per patient exceeds $39000 (for a limited screening
panel) and $57000 (for a full screening panel). As an alternative to both preoperative
screening and the status quo, we also estimated the break-even point for presumptively
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anticoagulating all free ﬂap candidates, which, at $49000, fell roughly midway between
the limited and full-screen watershed marks.
These ﬁndings are notable, given their implications for both the scope and impact of
thrombophilia conditions relative to free ﬂap surgery. If thrombophilias truly account for
nearly three quarters of thrombotic ﬂap complications, efforts to identify and treat free ﬂap
candidates with these conditions have the potential to signiﬁcantly reduce perioperative
morbidity in this patient cohort. What’s more, doing so may come at an overall cost that is
roughly equivalent to status quo practice—an observation that is particularly salient, given
increasing national attention on identifying and enacting medical practices deemed to be
cost-effective.
The utility in performing theoretical cost analyses requires comparing their results
to real cost data. While our break-even assessments provide an indication as to when our
posited intervention scenarios achieve efﬁciency equivalent to the status quo, the question
remains: what is the actual incremental cost of a thrombotic free ﬂap complication? Toward
this end, we have offered the results of a preliminary cost comparison analysis that provides
an initial approximation of $23000 per patient. This assessment is admittedly rudimentary
and does not likely capture the full scope of incremental costs associated with thrombotic
ﬂap complications; we expect more robust analyses performed in the future to demonstrate
a substantially higher value.
Providing this preliminary cost estimation does, however, allow us to begin to frame
discussions regarding preoperative screening and therapy relative to current practice in
a rational and meaningful manner. First, it permits the establishment of a benchmark
against which to judge the break-even analyses of our intervention scenarios. This, in turn,
allows us to tackle the question: how much will screening and treating free ﬂap candidates
cost relative to baseline? Our present analyses suggest a $14000 to $34000 per patient
differential between break even and baseline; with further investigation of direct costs,
however, we expect this differential to markedly reduce and, perhaps, cross the break-even
threshold. Second, it affords the capacity to assess the marginal utility of increased cost
relative to expected beneﬁt in the form of ICER analyses. This, in contrast, allows us
to tackle the question: how much expense is required to avert a single thrombotic ﬂap
complication? Our ICER estimations demonstrate incremental cost per avoided thrombotic
ﬂap complication results ranging from $15617 for the Limited Panel Scenario to $33638
for the Full Panel Scenario. These results illustrate the augmented cost-effectiveness of
targeted screening and treatment efforts and, as above, will likely decrease as more reliable
cost data is derived.
Forthepurposesofourstudy,itisassumedthatapositivethrombophiliascreeningtest
result for a given free ﬂap candidate would result in a change in baseline practice. Within
ourinstitution,enoxaparintherapyisendorsedbyhematologistsastheoptimalprophylactic
treatment regimen in free ﬂap patients who are known thrombophiliacs and was therefore
assumedbyustobetheinterventionofchoiceformodelingpurposes.Whilegeneralagree-
ment regarding the choice of enoxaparin exists, the duration of therapy remains debatable.
Conservative hematologists within our institution favor a 30-day course of prophylactic
therapy, yet a growing number of specialists have begun to argue for more limited (2 week)
regimens.Althoughourmodelassumesthemoreconservative30-dayregimen,substitution
with a 2-week therapy course would lead to a substantial reduction in our cost analyses
that would further favor the adoption of preoperative screening and therapy
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practices. In addition, it is possible that the employment of alternative therapeutic inter-
ventions for local anticoagulation (eg, ﬂap-directed heparinization or tissue plasminogen
activator administration) would offer lower-cost options of equivalent efﬁcacy that would
further inﬂuence our analyses.
There are several limitations of this study that must be acknowledged:
1. The determination of our institutional thrombotic ﬂap complication rate was predicated
upon the identiﬁcation of problematic cases based on the subjective assessment of the
operative surgeon as reﬂected in operative note. No objective means of conﬁrming
the assignation of a case as being of mechanical or nonmechanical thrombotic etiology
was possible.
2. Our analytic model is driven off of multiple assumptions regarding thrombophilia con-
ditions and therapeutic efﬁcacy that, while data-supported, remain open to debate. In
particular, the use of the relative risk of initial VTE as a proxy for the relative risk of
thrombotic complication for free ﬂap surgery may be an inaccurate assumption, and
further studies are warranted to determine the precise role of thrombophilias in the set-
ting of microsurgery. In addition, the potential for simultaneous coexistence of multiple
thrombophilias in the same theoretical patient is not captured, as little data regarding
coincidence rates of thrombophilias exists.
3. As described earlier, our institution-speciﬁc incremental cost of thrombotic ﬂap com-
plication calculation is admittedly rudimentary and deserves more detailed evaluation.
However, the current analysis likely underestimates the full incremental cost and, there-
fore, likely understates the efﬁciency and cost-effectiveness of intervention.
4. Our model excludes the cost of potential bleeding complications from administration of
therapeutic enoxaparin. However, a meta-analysis for extended enoxaparin prophylaxis
found no increase for pelvic and abdominal surgeries,28 and other studies have found
the rate of hematomas and postoperative bleeding to be small or not signiﬁcant relative
to controls. Thus, the best data for added complications from prophylaxis would have a
small to negligible inﬂuence on this model would and would not statistically inﬂuence
the estimates.
5. In accord with studies on VTE prophylaxis in other cohorts, in our model, we assume
88% efﬁcacy of therapeutic enoxaparin for those who test positive for thrombophilias.
The effectiveness of therapeutic anticoagulation may not be borne out in the setting of
microsurgery, and clinical trials are needed.
In light of these limitations, we submit this study as a means to begin, rather than
conclude, discussions regarding the potential cost-effectiveness of preoperative screening
and perioperative treatment for previously undiagnosed thrombophiliacs undergoing free
ﬂap procedures. Future studies directed at further elucidating the true thrombotic ﬂap com-
plication rate and marginal cost of thrombotic ﬂap complication are clearly warranted, as
are investigations to validate the use of VTE relative risks as proxy measures for spe-
ciﬁc thrombophilia conditions. We look forward to collaborating on such efforts in the
future.
287ePlasty VOLUME 11
REFERENCES
1. American Society of Plastic Surgeons, National Clearinghouse of Plastic Surgery Statistics. 2009 Report
of 2008 Statistics. Available at: www.plasticsurgery.org; December 1, 2009.
2. Bui DT, Cordeiro PG, Hu QY, Disa JJ, Pusic A, Mehrara BJ. Free ﬂap reexploration: indications, treatment,
and outcomes in 1193 free ﬂaps. Plast Reconstr Surg 2007;119(7):2092-100.
3. NieminenH,KuokkanenH,TukiainenE,Asko-SeljavaaraS.Freeﬂapreconstructionsof100tibialfractures.
J Trauma. 1999;46(6):1031-5.
4. DisaJJ,HuQY,HidalgoDA.Retrospectivereviewof400consecutivefreeﬂapreconstructionsforoncologic
surgical defects. Ann Surg Oncol. 1997;4(8):663-9.
5. Rinker B, Valerio IL, Stewart DH, Pu LL, Vasconez HC. Microvascular free ﬂap reconstruction in pediatric
lower extremity trauma: a 10-year review. Plast Reconstr Surg. 2005;115(6):1618-24.
6. Kroll SS, Reece GP, Miller MJ, et al. Timing of pedicle thrombosis and ﬂap loss after free-tissue transfer.
Plast Reconstr Surg. 1996;98(7):1230-3.
7. Chen KT, Mardini S, Chuang DC, et al. Timing of presentation of the ﬁrst signs of vascular compromise
dictates the salvage outcome of free ﬂap transfers. Plast Reconstr Surg. 2007;120(1):187-95.
8. Avery C. Prospective study of the septocutaneous radial free ﬂap and suprafascial donor site. Br J Oral
Maxillofac Surg. 2007;45(8):611-6.
9. Khouri RK, Cooley BC, Kunselman AR, et al. A prospective study of microvascular free-ﬂap surgery and
outcome. Plast Reconstr Surg. 1998;102(3):711-21.
10. Nicoletti G, Gamba G, Scevola S, Faga A. The congenital deﬁcit of protein S as a new prognostic factor in
microsurgery. Plast Reconstr Surg. 2005;116(6):1837-8.
11. Davis MR, Shell DH IV , Marques M, Long JN. Free ﬂap failure secondary to dual thrombophilia. Micro-
surgery. 2009;29(1):62-5.
12. Davison SP, Kessler CM, Al-Attar A. Microvascular free ﬂap failure caused by unrecognized hypercoagu-
lability. Plast Reconstr Surg. 2009;124(2):490-5.
13. Olsson EH, Tukiainen E. Three-year evaluation of late breast reconstruction with a free transverse rectus
abdominis musculocutaneous ﬂap in a county hospital in Sweden: a retrospective study. Scand J Plast
Reconstr Surg Hand Surg. 2005;39(1):33-8.
14. Salgarello M, Cervelli D., Barone-Adesi L. A massive arterial thrombosis of a free anterolateral thigh ﬂap
in a patient with antiphospholipid syndrome. Microsurgery. 2008;28(6):447-51.
15. Friedman T, O’Brien Coon D, Michaels VJ, et al. Hereditary coagulopathies: practical diagnosis and
management for the plastic surgeon. Plast Reconstr Surg. 2010;125(5):1544-52.
16. AyalaC,BlackwellKE.ProteinCdeﬁciencyinmicrovascularheadandneckreconstruction.Laryngoscope.
1999;109(2 pt 1):259-65.
17. Arnljots B, Soderstrom T, Svensson H. No correlation between activated protein C resistance and free ﬂap
failures in 100 consecutive patients. Plast Reconstr Surg. 1998;101(7):1850-3.
18. Lijfering WM, Brouwer J-LP, Veeger NJGM, et al. Selective testing for thrombophilia in patients with
ﬁrst venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for
currently known thrombophilic defects in 2479 relatives. Blood. 2009;113(21):5314-22.
19. De Stefano, V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and
therapeutic implications. Haematologica. 2002;87(10):1095-108.
20. Simioni, P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited
thrombophilia. Thromb Haemost. 1999;81(2):198-202.
21. Weitz JI, Middeldorp S, Geerts W, Heit JA. Thrombophilia and new anticoagulant drugs. Hematol Am Soc
Hematol Educ Program. 2004:424-38.
22. Uppal RS, Stillaert FB, Hamdi M. Antiphospholipid syndrome—a rare cause of free ﬂap thrombosis in
perforator ﬂap breast reconstruction. J Plast Reconstr Aesthet Surg. 2008;61(3):347-8.
23. Nagaraja D. Noone ML, Bharatkumar VP, Christopher R. Homocysteine, folate and vitamin B(12) in
puerperal cerebral venous thrombosis. J Neurol Sci. 2008;272(1-2):43-7.
24. Pruemer J. Prevalence, causes, and impact of cancer-associated thrombosis. Am J Health Syst Pharm.
2005;62(22)(suppl 5):S4-S6.
25. Knudson MM., Ikossi DG. Venous thromboembolism after trauma. Curr Opin Crit Care. 2004;10(6):539-
48.
288BOWMAN AND CARTY
26. Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family
members who are carriers of factor V Leiden: a prospective cohort study. Blood. 2002;99(6):1938-42.
27. Rosendaal FR. Venous thrombosis: prevalence and interaction of risk factors. Haemostasis. 1999 29
(Suppl S1): 1-9.
28. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged thromboprophylaxis with low molecular
weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2009;(1):CD004318.
289